Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine crossover study in multiple sclerosis with internuclear ophthalmoplegia
NL-OMON42310Phase 2Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dalfampridine in multiple sclerosis (MS) (2 arms), sponsored by Centre for Human Drug Research. Primary endpoint: Eye movement measures. Started Apr 2015; status: active, not recruiting.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON42310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42310.